The Effect of Rehabilitation Training on Orthostatic Hypotension in Parkinson's Patients
Launched by ZENG CHANGHAO · Feb 4, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a special type of training called "raise-bed training" can help improve a condition known as orthostatic hypotension in patients with Parkinson's disease. Orthostatic hypotension is when a person feels dizzy or lightheaded after standing up, which happens because their blood pressure drops too much. The trial will last for 21 days, and participants will be randomly placed into two groups: one will receive the raise-bed training, while the other will continue with standard rehabilitation treatment. Researchers will measure how well this training helps improve symptoms by using various questionnaires and scales.
To be eligible for this study, participants must be at least 40 years old, have a confirmed diagnosis of Parkinson's disease, and experience orthostatic hypotension. They should be able to give their consent to join the study. However, those with certain serious medical conditions, on specific blood pressure medications, or with recent history of fainting or falls may not qualify. This study aims to understand if the raise-bed training can make a positive difference in managing orthostatic hypotension for those living with Parkinson's disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Confirmed diagnosis of Parkinson's disease
- • Presence of orthostatic hypotension, defined as a decrease in systolic blood pressure of at least 20 mmHg or a decrease in diastolic blood pressure of at least 10 mmHg within three minutes of standing up
- • Age 40 years or older
- • Willingness to participate in the study and provide informed consent
- Exclusion Criteria:
- • Severe cardiovascular disease or other medical conditions that would make head-up tilt treatment unsafe or inappropriate
- • Use of medications that affect blood pressure or heart rate, such as beta-blockers or vasodilators, and inability or unwillingness to discontinue these medications for the study period
- • History of syncope or falls within the past six months
- • Inability to stand or sit up independently or tolerate changes in body position
- • Cognitive impairment or inability to provide informed consent
About Zeng Changhao
Zeng Changhao is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous and ethically conducted clinical studies. With a commitment to improving patient outcomes, Zeng Changhao collaborates with leading healthcare professionals and research institutions to explore novel therapies and treatment modalities. The organization emphasizes transparency, compliance, and patient safety, ensuring that all trials adhere to the highest regulatory standards. Through its strategic partnerships and a patient-centric approach, Zeng Changhao aims to contribute significantly to the development of effective and safe healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Mianyang, Henan, China
Beijing, Beijing, China
Zhenzhou, Henan, China
Xinzhu, , Taiwan
Patients applied
Trial Officials
Nieto Luis, Master
Study Director
Site Coordinator of United Medical Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported